Renaissance Group LLC Invests $8.54 Million in TransMedics Group, Inc. $TMDX

Renaissance Group LLC bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 76,078 shares of the company’s stock, valued at approximately $8,536,000.

Several other hedge funds have also bought and sold shares of the stock. Whittier Trust Co. of Nevada Inc. increased its position in TransMedics Group by 981.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after buying an additional 206 shares in the last quarter. Salomon & Ludwin LLC bought a new position in shares of TransMedics Group during the 3rd quarter valued at approximately $28,000. Pilgrim Partners Asia Pte Ltd bought a new position in shares of TransMedics Group during the 3rd quarter valued at approximately $40,000. First Horizon Corp purchased a new stake in TransMedics Group in the 3rd quarter worth approximately $43,000. Finally, Elevation Point Wealth Partners LLC purchased a new position in TransMedics Group during the second quarter valued at approximately $48,000. Institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

TMDX has been the subject of a number of analyst reports. Morgan Stanley increased their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Needham & Company LLC increased their price target on TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Jefferies Financial Group began coverage on TransMedics Group in a research report on Monday, October 13th. They issued a “buy” rating and a $145.00 price objective on the stock. Canaccord Genuity Group upped their price objective on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Finally, Piper Sandler reissued an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, TransMedics Group presently has an average rating of “Moderate Buy” and a consensus target price of $144.25.

Insider Buying and Selling at TransMedics Group

In related news, Director David Weill sold 5,000 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total transaction of $693,200.00. Following the sale, the director owned 12,134 shares in the company, valued at approximately $1,682,257.76. This represents a 29.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Gerardo Hernandez sold 920 shares of TransMedics Group stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40. Following the transaction, the chief financial officer directly owned 15,064 shares of the company’s stock, valued at $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 8,920 shares of company stock worth $1,257,310 over the last ninety days. Company insiders own 7.00% of the company’s stock.

TransMedics Group Stock Up 4.2%

Shares of NASDAQ TMDX opened at $135.06 on Friday. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43. TransMedics Group, Inc. has a 12-month low of $62.07 and a 12-month high of $156.00. The firm’s 50-day moving average price is $133.12 and its 200-day moving average price is $124.36. The stock has a market capitalization of $4.62 billion, a price-to-earnings ratio of 54.68 and a beta of 2.06.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.